Agios Pharmaceuticals assumed with a Perform at Oppenheimer. Oppenheimer analyst Mark Breidenbach assumed coverage of Agios Pharmaceuticals with a Perform rating. While the analyst believes the company has the hallmarks of a long-term success story, he views the commercial potential of its lead programs as fairly reflected in Agios’ current market capitalization.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.